Zoledronic Acid Administration in Acute Spinal Cord Injury
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
In subjects with acute SCI: To compare the effects of parenteral zoledronic acid therapy on
preservation of regional and total skeletal mass (DXA).
Hypothesis: Zoledronic acid will dramatically diminish bone loss in persons with acute SCI,
as evidenced by serial densitometry determinations (DXA).